Revvity, Inc. (NYSE: RVTY), a supplier of well being science options and applied sciences, on Monday reported a rise in revenues for the second quarter of 2025.
- On a reported foundation, second-quarter earnings had been $0.46 per share, in comparison with $0.45 in the identical interval a 12 months in the past
- Adjusted earnings per share from persevering with operations dropped to $1.18 from $1.22 a 12 months earlier
- Second-quarter income elevated to about $720 million from $692 million within the prior-year quarter
- Life Sciences revenues elevated 5% yearly to $366 million within the second quarter; Diagnostics income rose 3% to $354 million
- Working earnings from persevering with operations, on a reported foundation, was $91 million, vs. $86 million in Q2 FY24
- For the complete 12 months 2025, the corporate raised its full-year income steerage to $2.84-$2.88 billion to mirror current adjustments in overseas forex trade charges; it assumes 2% to 4% natural progress
- The administration additionally up to date its adjusted earnings per share steerage to a spread of $4.85 to $4.95
